Journal watch is good in keep me updating.
Do you accept case report for publication and if so what's the limit of the word?
FDA Grants Apixaban Expanded Indication for Venous Thromboembolism — Physician’s First Watch
FDA Grants Apixaban Expanded Indication for Venous Thromboembolism
By Larry Husten
The FDA has approved an expanded indication for the oral anticoagulant apixaban (Eliquis), the manufacturer announced late last week. Apixaban will now be indicated for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk for recurrent DVT and PE after initial therapy.
Approval of the supplemental new drug application was based on findings from the previously published AMPLIFY and AMPLIFY-EXT studies.
All three of the new oral anticoagulants — dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban — have now gained both the venous thromboembolism indication as well as the indication for stroke prevention in patients with nonvalvular atrial fibrillation. Rivaroxaban and apixaban are also approved for DVT prophylaxis following hip- or knee-replacement surgery.